RPh 201

Drug Profile

RPh 201

Alternative Names: RPh201

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regenera Pharma
  • Developer Hadassah Medical Organization; Regenera Pharma
  • Class Antidementias; Herbal medicines
  • Mechanism of Action G protein-coupled receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Optic nerve disorders
  • Phase II Alzheimer's disease
  • No development reported Persistent vegetative state
  • Discontinued Chronic wounds

Most Recent Events

  • 03 Aug 2018 RPh 201 receives Fast Track designation for Optic nerve disorders [SC] (In the elderly, In adults) in USA
  • 02 Aug 2018 Regenera Pharma has global patent protection for RPh 201
  • 02 Aug 2018 Efficacy data from a phase II trial in Optic nerve disorders released by Regenera Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top